BIODESIX INC — Director's Dealing 2022

Mar 18, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIODESIX INC (BDSX)
CIK: 0001439725
Period of Report: 2021-02-23

Reporting Person: Georgantas Robert William III (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-23	Stock Options (Right to buy)	$0.77	A	2843	Acquired	2030-04-14	Common Stock (2843)	Direct
2022-03-10	Stock Options (Right to buy)	$0.77	A	2842	Acquired	2030-04-14	Common Stock (2842)	Direct

Footnotes

F1: On April 15, 2020, the Reporting Person was granted an option to purchase 5,685 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2020 and 2021 fiscal years.

F2: On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 2,843 shares underlying the option.

F3: On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 2,842 shares underlying the option.